Teva Pharmaceutical Industries (TEVA) Receivables (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Receivables for 18 consecutive years, with $3.5 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables fell 1.99% year-over-year to $3.5 billion; the trailing twelve-month figure through Jun 2026 stood at $3.5 billion (down 1.99% YoY), and the FY2025 full-year result was $3.7 billion, up 21.25% from the prior year.
• Receivables rose to $3.5 billion in Q2 2026 per TEVA's latest filing, from $3.4 billion in the prior quarter.
• Across five years, Receivables topped out at $4.5 billion in Q2 2022 and bottomed at $3.1 billion in Q4 2024.
• Historically, Receivables has averaged $3.6 billion across 5 years, with a median of $3.5 billion in 2023.
• The sharpest annual moves came in 2023 and 2025: Receivables slipped 20.85% in 2023, then gained 21.25% in 2025.
• Over 5 years, Receivables stood at $3.7 billion in 2022, then slipped by 7.79% to $3.4 billion in 2023, then declined by 10.24% to $3.1 billion in 2024, then rose by 21.25% to $3.7 billion in 2025, then declined by 5.82% to $3.5 billion in 2026.
• According to Business Quant data, Receivables over the past three periods registered $3.5 billion, $3.4 billion, and $3.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.